Compare Cassava Sciences Inc (FLNA) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs T Rowe Price Group Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while T Rowe Price Group Inc trades at $116.99 (market cap $24.27B). The key difference: T Rowe Price Group Inc is far larger — about 508.3× Cassava Sciences Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TROW | |
|---|---|---|
Market Cap | $47.75M | $24.27B |
Sector | Health | Financials |
52-Week High | $4.64 | $121.68 |
52-Week Low | $0.87 | $86.19 |
Enterprise Value | -$34.93M | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
T. Rowe Price (TROW) trades at $114.02, up 0.35% today, with a neutral technical outlook and mixed analyst sentiment. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51, driven by record assets under management and higher advisory fees. The stock trades at a P/E of 11.45, below industry averages, indicating potential undervaluation. Dividend payments remain stable at $1.30 per share, supporting income investors.
Outlook is cautiously optimistic given strong profitability metrics like a 29.26% net income margin and 20.1% ROE, but risks include expense pressures and net outflows. Analyst consensus price target is $112.17, slightly below current price, with 63% hold ratings suggesting limited near-term upside. Investors should weigh solid fundamentals against competitive headwinds in the asset management sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
